Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses

Journal of Immunological Methods

Volumn 275, Issue 1-2, 2003, Pages 19-29

  Draenert, Rika ^a   Altfeld, Marcus ^a   Brander, Christian ^a   Basgoz, Nesli ^a   Corcoran, Colleen ^a   Wurcel, Alysse G ^a,b   Stone, David R ^b   Kalams, Spyros A ^a   Trocha, Alicja ^a   Addo, Marylyn M ^a   Goulder, Philip J R ^a,c   Walker, Bruce D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b LEMUEL SHATTUCK HOSPITAL   (United States)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

CD8 and CD4 T cell responses; Elispot assay; Intracellular cytokine staining assay; Overlapping peptides

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; NEF PROTEIN; PEPTIDE;

ARTICLE; ASSAY; CELLULAR IMMUNITY; CLADISTICS; COMPARATIVE STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; STAINING; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0037377309     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00541-0     Document Type: Article

References (23)

1. Addo M.M., Altfeld M., Rosenberg E.S., Eldridge R.L., Philips M.N., Habeeb K., Khatri A., Brander C., Robbins G.K., Mazzara G.P., Goulder P.J., Walker B.D. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1781-1786.
2. Alexander J., Oseroff C., Dahlberg C., Qin M., Ishioka G., Beebe M., Fikes J., Newman M., Chesnut R.W., Morton P.A., Fok K., Appella E., Sette A. A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J. Immunol. 168:2002;6189-6198.
3. Altfeld M.A., Trocha A., Eldridge R.L., Rosenberg E.S., Phillips M.N., Addo M.M., Sekaly R.P., Kalams S.A., Burchett S.A., McIntosh K., Walker B.D., Goulder P.J. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay. J. Virol. 74:2000;8541-8549.
4. Altfeld M., Addo M.M., Eldridge R.L., Yu X.G., Thomas S., Khatri A., Strick D., Phillips M.N., Cohen G.B., Islam S.A., Kalams S.A., Brander C., Goulder P.J., Rosenberg E.S., Walker B.D. Vpr is preferentially targeted by CTL during HIV-1 infection. J. Immunol. 167:2001;2743-2752.
5. Betts M.R., Ambrozak D.R., Douek D.C., Bonhoeffer S., Brenchley J.M., Casazza J.P., Koup R.A., Picker L.J. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75:2001;11983-11991.
6. Brander C., O'Connor P., Suscovich T., Jones N.G., Lee Y., Kedes D., Ganem D., Martin J., Osmond D., Southwood S., Sette A., Walker B.D., Scadden D.T. Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J. Infect. Dis. 184:2001;119-126.
7. Casimiro D.R., Tang A., Perry H.C., Long R.S., Chen M., Heidecker G.J., Davies M.E., Freed D.C., Persaud N.V., Dubey S., Smith J.G., Havlir D., Richman D., Chastain M.A., Simon A.J., Fu T.M., Emini E.A., Shiver J.W. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J. Virol. 76:2002;185-194.
8. Couillin I., Letourneur F., Lefebvre P., Guillet J.G., Martinon F. DNA vaccination of macaques with several different Nef sequences induces multispecific T cell responses. Virology. 279:2001;136-145.
9. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods. 65:1983;109-121.
10. Dalod M., Dupuis M., Deschemin J.C., Goujard C., Deveau C., Meyer L., Ngo N., Rouzioux C., Guillet J.G., Delfraissy J.F., Sinet M., Venet A. Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J. Clin. Invest. 104:1999;1431-1439.
11. Dunn H.S., Haney D.J., Ghanekar S.A., Stepick-Biek P., Lewis D.B., Maecker H.T. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J. Infect. Dis. 186:2002;15-22.
12. Edwards B.H., Bansal A., Sabbaj S., Bakari J., Mulligan M.J., Goepfert P.A. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 76:2002;2298-2305.
13. Evans D.T., Jing P., Allen T.M., O'Connor D.H., Horton H., Venham J.E., Piekarczyk M., Dzuris J., Dykhuzen M., Mitchen J., Rudersdorf R.A., Pauza C.D., Sette A., Bontrop R.E., DeMars R., Watkins D.I. Definition of five new simian immunodeficiency virus cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I molecules: evidence for an influence on disease progression. J. Virol. 74:2000;7400-7410.
14. Ferrari G., Neal W., Jones A., Olender N., Ottinger J., Ha R., McElrath M.J., Goepfert P., Weinhold K.J. CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. Immunol. Lett. 79:2001;37-45.
15. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B.H., Bhattacharya T., Korber B. Diversity considerations in HIV-1 vaccine selection. Science. 296:2002;2354-2360.
16. Goulder P.J., Tang Y., Brander C., Betts M.R., Altfeld M., Annamalai K., Trocha A., He S., Rosenberg E.S., Ogg G., O'Callaghan C.A., Kalams S.A., McKinney R.E. Jr., Mayer K., Koup R.A., Pelton S.I., Burchett S.K., McIntosh K., Walker B.D. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J. Exp. Med. 192:2000;1819-1832.
17. Lauer G.M., Ouchi K., Chung R.T., Nguyen T.N., Day C.L., Purkis D.R., Reiser M., Kim A.Y., Lucas M., Klenerman P., Walker B.D. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J. Virol. 76:2002;6104-6113.
18. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., Persaud N., Trigona W., Fu T.M., Sinclair E., Bredt B.M., McCune J.M., Maino V.C., Kern F., Picker L.J. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods. 255:2001;27-40.
19. Meij P., Leen A., Rickinson A.B., Verkoeijen S., Vervoort M.B., Bloemena E., Middeldorp J.M. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int. J. Cancer. 99:2002;93-99.
20. Scheibenbogen C., Sun Y., Keilholz U., Song M., Stevanovic S., Asemissen A.M., Nagorsen D., Thiel E., Rammensee H.G., Schadendorf D. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int. J. Cancer. 98:2002;409-414.
21. Schmechel S.C., Russell N., Hladik F., Lang J., Wilson A., Ha R., Desbien A., McElrath M.J. Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons. Immunol. Lett. 79:2001;21-27.
22. Schmittel A., Keilholz U., Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods. 210:1997;167-174.
23. Seki N., Brooks A.D., Carter C.R., Back T.C., Parsoneault E.M., Smyth M.J., Wiltrout R.H., Sayers T.J. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168:2002;3484-3492.